Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase Inhibitor (TKI) at the European Society for Clinical Oncology (ESMO) Congress
BEIJING--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd. (“Avistone†or “the Companyâ€), a clinical-stage biotechnology company focused on…